AI assistant
MEMPHASYS LIMITED. — Capital/Financing Update 2019
Mar 25, 2019
65314_rns_2019-03-25_389763ca-3cfa-4a4a-b0c5-83fac52f8177.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [222 x 64] intentionally omitted <==
ASX Release 26 March 2019
Rights Issue Prospectus Shortfall
Pursuant to the Non-renounceable Rights Issue Prospectus dated 28 February 2019 and lodged with ASIC and ASX on same day, the rights offer closed on 21 March 2019.
A total of 182,044,573 rights to shares were offered under the Rights Issue and as at the closing date, 94,736,774 rights to shares were accepted.
The shortfall of 87,307,799 rights to shares are to be placed by the underwriter to the offer, Patersons Securities Limited.
For further information please contact:
Alison Coutts David Tasker Executive Chairman Managing Director Memphasys Limited Chapter One Advisors +61 2 8415 7300 +0433 112 936 [email protected] [email protected]
About Memphasys:
Memphasys Limited (ASX: MEM) specialises in biological separations for high value commercial applications. The Company’s patented membrane processes in combination with electrophoresis, the application of an electrical potential difference across a fluid, enable the separation of high value substances or contaminants from the fluid in which they are contained.
The main application of the technology is the separation of the most viable sperm cells for artificial reproduction, most particularly for human IVF.
Postal Address Contact Details P.O. Box 2202 P +612 8415 7300 Homebush West NSW 2140 F +612 8415 7399
E [email protected] W memphasys.com ABN 33 120 047 556
Memphasys Limited 30-32 Richmond Road Homebush West NSW 2140